Literature DB >> 3791198

Combination immunotherapy of cancer in a mouse model: synergism between tumor necrosis factor and other defense systems.

M Chun, M K Hoffmann.   

Abstract

Bacterial lipopolysaccharide (LPS) induces the release of factors into the serum which enable mice to reject experimental tumors. One such factor is tumor necrosis factor which causes acute necrosis of syngeneic sarcoma transplants in mice. Effective therapeutic use of tumor necrosis factor is limited, however, by its toxicity. We show here that the efficacy of tumor necrosis factor can be substantially increased by combining its application with low doses of LPS. Our data suggest that LPS exerts its antitumor effects by engaging more than one defense mechanism. Characteristic for the activation of a biological system is a concomitant induction of negative feedback mechanisms which antagonize the initial stimulus. Interference with the negative feedback response may substantially increase biological reactions. We show here that the blocking of two negative feedback responses occurring as a consequence of treatment with LPS, namely the production of prostaglandin E and the generation of suppressor T-lymphocytes, increases dramatically the ability of mice to reject tumor transplants. Thus, through appropriate combination of different factors one may reduce the dose of each below toxic levels and through interference with negative feedback responses increase the efficacy of antitumor reagents. We consider our findings in the context of formulating an effective immunotherapy of malignancies and as a promising step toward it.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3791198

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

1.  Inactivation of suppressor T-cell activity by nontoxic monophosphoryl lipid A.

Authors:  P J Baker; J R Hiernaux; M B Fauntleroy; B Prescott; J L Cantrell; J A Rudbach
Journal:  Infect Immun       Date:  1988-05       Impact factor: 3.441

2.  Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

Authors:  P A van de Wiel; R H Pieters; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Mycoplasma capricolum membranes induce tumor necrosis factor alpha by a mechanism different from that of lipopolysaccharide.

Authors:  T Sher; S Rottem; R Gallily
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

4.  Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.

Authors:  L M Ching; W R Joseph; L Zhuang; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

5.  Effect of tumour necrosis factor and lipid A on functional and structural vascular volume in solid murine tumours.

Authors:  P A van de Weil; G J Bouma; A van der Pijl; E S Weitenberg; A W Lam; N Bloksma
Journal:  Br J Cancer       Date:  1990-11       Impact factor: 7.640

6.  Acetylsalicylic acid (ASA) protects the prostaglandin-cAMP-system of human hypernephroma cells against irradiation-induced alterations.

Authors:  S R Li; Q Yang; E Wandl; W Pirker; I Virgolini
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.